169 related articles for article (PubMed ID: 31620896)
1. Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study.
Guadagni S; Fiorentini G; De Simone M; Masedu F; Zoras O; Mackay AR; Sarti D; Papasotiriou I; Apostolou P; Catarci M; Clementi M; Ricevuto E; Bruera G
J Cancer Res Clin Oncol; 2020 Jan; 146(1):205-219. PubMed ID: 31620896
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study.
Guadagni S; Fiorentini G; Mambrini A; Masedu F; Valenti M; Mackay AR; Sarti D; Ricevuto E; Clementi M; Catarci M; Lazzarin G; Bruera G
Oncotarget; 2019 Jun; 10(39):1-13. PubMed ID: 31231460
[TBL] [Abstract][Full Text] [Related]
3. Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.
Guadagni S; Clementi M; Mackay AR; Ricevuto E; Fiorentini G; Sarti D; Palumbo P; Apostolou P; Papasotiriou I; Masedu F; Valenti M; Giordano AV; Bruera G
J Cancer Res Clin Oncol; 2020 May; 146(5):1273-1290. PubMed ID: 32088781
[TBL] [Abstract][Full Text] [Related]
4. Palliation with a multimodality treatment including hypoxic pelvic perfusion for unresectable recurrent rectal cancer: outcomes based on a retrospective study.
Guadagni S; Clementi M; Bencivenga M; Kusamura S; Fiorentini C; Masedu F
Updates Surg; 2018 Dec; 70(4):441-447. PubMed ID: 30191532
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases.
Guadagni S; Masedu F; Fiorentini G; Sarti D; Fiorentini C; Guadagni V; Apostolou P; Papasotiriou I; Parsonidis P; Valenti M; Ricevuto E; Bruera G; Farina AR; Mackay AR; Clementi M
BMC Cancer; 2022 Jun; 22(1):660. PubMed ID: 35710393
[TBL] [Abstract][Full Text] [Related]
6. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
Guadagni S; Fiorentini G; Palumbo P; Masedu F; Ricevuto E; Bruera G; Deraco M; Kusamura S; Sarti D; Fiorentini C; Gailhofer S; Clementi M
Minerva Chir; 2019 Aug; 74(4):304-312. PubMed ID: 31062943
[TBL] [Abstract][Full Text] [Related]
7. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study.
Guadagni S; Fiorentini G; Papasotiriou I; Apostolou P; Masedu F; Sarti D; Farina AR; Mackay AR; Clementi M
BMC Res Notes; 2020 Mar; 13(1):176. PubMed ID: 32204733
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Kim SH; Kim JH; Jung SH
Int J Colorectal Dis; 2015 Sep; 30(9):1193-9. PubMed ID: 26072129
[TBL] [Abstract][Full Text] [Related]
10. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
13. The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.
Baird DLH; Denost Q; Simillis C; Pellino G; Rasheed S; Kontovounisios C; Tekkis PP; Rullier E
Colorectal Dis; 2017 Nov; 19(11):980-986. PubMed ID: 28493401
[TBL] [Abstract][Full Text] [Related]
14. Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.
Valentini V; van Stiphout RG; Lammering G; Gambacorta MA; Barba MC; Bebenek M; Bonnetain F; Bosset JF; Bujko K; Cionini L; Gerard JP; Rödel C; Sainato A; Sauer R; Minsky BD; Collette L; Lambin P
Radiother Oncol; 2015 Mar; 114(3):302-9. PubMed ID: 25716096
[TBL] [Abstract][Full Text] [Related]
15. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
16. Tumor location as an indication for adjuvant radiotherapy in pT3N0 rectal cancer after surgery.
Peng HH; Zhou XH; Zhou TC; Qiu XS; You KY
Radiat Oncol; 2019 Jan; 14(1):8. PubMed ID: 30651116
[TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
18. The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study.
Li Q; Peng Y; Wang LA; Wei X; Li MX; Qing Y; Xia W; Cheng M; Zi D; Li CX; Wang D
Tumour Biol; 2016 Mar; 37(3):3441-9. PubMed ID: 26449827
[TBL] [Abstract][Full Text] [Related]
19. Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
Lee WC; Yusof MM; Lau FN; Phua VC
Asian Pac J Cancer Prev; 2013; 14(6):3941-4. PubMed ID: 23886211
[TBL] [Abstract][Full Text] [Related]
20. A Pilot Study of the Predictive Potential of Chemosensitivity and Gene Expression Assays Using Circulating Tumour Cells from Patients with Recurrent Ovarian Cancer.
Guadagni S; Clementi M; Masedu F; Fiorentini G; Sarti D; Deraco M; Kusamura S; Papasotiriou I; Apostolou P; Aigner KR; Zavattieri G; Farina AR; Vizzielli G; Scambia G; Mackay AR
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32646060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
